The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2022 | The role of tandem transplantation in multiple myeloma & how this may be impacted by novel agents
Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, discusses the role of tandem autologous stem cell transplantation (autoSCT) in patients with multiple myeloma, and discusses clinical trials in this space, including the STaMINA trial (NCT02322320). Dr Voorhees explains that while tandem transplant may benefit patients with high-risk cytogenetics, its role in multiple myeloma will be impacted with the emergence of novel agents and immunotherapies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
